EMPRI L 10/5 10S

About

This medication combines Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin works by inhibiting SGLT2 in the kidneys, leading to increased glucose excretion in the urine, thereby lowering blood glucose levels and providing significant cardiovascular and renal protective effects. Linagliptin enhances the body's natural ability to lower high blood sugar by increasing the levels of active incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. This combination offers a complementary mechanism of action to achieve comprehensive glycemic control in adults with type 2 diabetes. It is particularly useful for patients who need improved blood sugar management and may benefit from the additional cardiovascular and renal advantages of Empagliflozin.

Uses

• Management of type 2 diabetes mellitus in adults.
• To improve glycemic control when diet and exercise are insufficient.
• As an add-on therapy to other antidiabetic medications.
• To reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.

Directions For Use

Take one tablet orally once daily, with or without food, as directed by your physician.

Benefits

• Provides effective blood sugar control.
• Reduces HbA1c levels.
• Offers cardiovascular and renal protective benefits.
• Low risk of hypoglycemia when used alone.
• Convenient once-daily dosing.
• Does not require dose adjustment for kidney impairment (Linagliptin component).

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Nausea
• Diarrhea
• Headache
• Joint pain
• Runny nose or sore throat
• Hypoglycemia (when used with insulin or sulfonylureas)
• Ketoacidosis (rare)
• Pancreatitis (rare)
• Serious allergic reactions

Safety Measures

• Alcohol - Moderate alcohol intake is generally acceptable. Excessive consumption may increase the risk of hypoglycemia. Consult your doctor.
• Pregnancy - Not recommended during pregnancy. Consult your doctor immediately if you become pregnant or plan to conceive.
• Breastfeeding - It is unknown if components pass into breast milk. Avoid during breastfeeding or consult your doctor for advice.
• Liver - Use with caution in patients with hepatic impairment. No dose adjustment is typically needed for Linagliptin in liver impairment.
• Kidney - Dose adjustment for Empagliflozin may be required based on kidney function. Linagliptin does not require dose adjustment in renal impairment.
• Lung - Generally safe for use in patients with lung conditions. No specific contraindications related to lung function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.